×
+ All Categories
Log in
English
Français
Español
Deutsch
Report -
ADA 2018 outline - Novo Nordisk · ADA 2018 investor presentation 59% 72% 80% 34% 0% 20% 40% 60% 80% 100% Oral sema 3 mg Oral Sema 7 mg Oral sema 14 mg Placebo Proportion of patients
Name
Email
Select
Select
Pornographic
Defamatory
Illegal/Unlawful
Spam
Other Terms Of Service Violation
File a copyright complaint
Message
Please pass captcha verification before submit form